Medicare GLP-1 Bridge Initiative: Affordable Weight-Loss Medications
As of July 1, 2026, a groundbreaking pilot program under Medicare has launched, providing Part D prescription plan enrollees with access to specific weight-loss medications at a reduced cost. Named the Medicare GLP-1 Bridge initiative, this program aims to improve accessibility of these medications through a $50 monthly copay and is scheduled to run for 18 months, concluding on December 31, 2027.
The Medicare GLP-1 Bridge initiative targets medications within the glucagon-like peptide-1 (GLP-1) receptor agonists category, which are often financially burdensome due to their high out-of-pocket costs. Covered medications include Foundayo (orforglipron) tablets, Wegovy (semaglutide) pills and injections, and Zepbound (tirzepatide) KwikPens. Notably, other forms such as Zepbound single-use pens and Ozempic, which is FDA-approved for Type 2 diabetes, remain excluded from this initiative.
Eligibility for the program mandates that participants must be at least 18 years old, enrolled in a Medicare Part D plan, and prescribed a qualifying GLP-1 medication for weight reduction and maintenance. Furthermore, they must agree to lifestyle changes, including nutrition and physical activity plans, consistent with the medication's use regimen.
Enrollment in the program is open to individuals in standalone Part D plans or Medicare Advantage plans with Part D coverage. Special Needs Plans and employer group waiver plans also qualify, whereas programs like PACE are ineligible unless a standalone Part D plan is involved. Dually eligible individuals for both Medicare and Medicaid can participate, provided they meet all necessary criteria.
The program requires a prior authorization process, where providers must submit pertinent documentation to gain medication access. These prescriptions, typically for a 28- or 30-day supply, necessitate both a prescription and possibly additional forms to ensure compliance with clinical criteria.
Looking ahead, while the Medicare GLP-1 Bridge program is set to conclude by December 2027, discussions around a subsequent phase named BALANCE have surfaced, suggesting a five-year extension beginning in 2027. Nevertheless, the future beyond this date remains uncertain and is contingent on upcoming decisions by the Centers for Medicare & Medicaid Services.
This initiative marks a significant development for eligible Medicare beneficiaries seeking cost-effective, sustainable weight-loss medications, addressing a crucial gap that has long persisted within the Medicare system's offerings.